 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.220
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 6 | 6 | | 1981 | 0 | 6 | 6 | | 1982 | 0 | 8 | 8 | | 1983 | 0 | 6 | 6 | | 1984 | 0 | 4 | 4 | | 1985 | 0 | 8 | 8 | | 1986 | 0 | 7 | 7 | | 1987 | 0 | 12 | 12 | | 1988 | 0 | 10 | 10 | | 1989 | 0 | 18 | 18 | | 1990 | 0 | 24 | 24 | | 1991 | 0 | 26 | 26 | | 1992 | 0 | 28 | 28 | | 1993 | 0 | 39 | 39 | | 1994 | 0 | 29 | 29 | | 1995 | 0 | 29 | 29 | | 1996 | 0 | 21 | 21 | | 1997 | 0 | 32 | 32 | | 1998 | 0 | 32 | 32 | | 1999 | 0 | 35 | 35 | | 2000 | 0 | 47 | 47 | | 2001 | 0 | 58 | 58 | | 2002 | 0 | 75 | 75 | | 2003 | 1 | 72 | 73 | | 2004 | 0 | 78 | 78 | | 2005 | 0 | 69 | 69 | | 2006 | 0 | 64 | 64 | | 2007 | 0 | 66 | 66 | | 2008 | 1 | 67 | 68 | | 2009 | 1 | 55 | 56 | | 2010 | 0 | 61 | 61 | | 2011 | 0 | 55 | 55 | | 2012 | 0 | 57 | 57 | | 2013 | 0 | 42 | 42 | | 2014 | 0 | 50 | 50 | | 2015 | 3 | 42 | 45 | | 2016 | 0 | 38 | 38 | | 2017 | 0 | 30 | 30 | | 2018 | 0 | 29 | 29 | | 2019 | 0 | 9 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Wechsler ME, Szefler SJ, Ortega VE, Pongracic JA, Chinchilli V, Lima JJ, Krishnan JA, Kunselman SJ, Mauger D, Bleecker ER, Bacharier LB, Beigelman A, Benson M, Blake KV, Cabana MD, Cardet JC, Castro M, Chmiel JF, Covar R, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Grossman N, Holguin F, Jackson DJ, Kumar H, Kraft M, LaForce CF, Lang J, Lazarus SC, Lemanske RF, Long D, Lugogo N, Martinez F, Meyers DA, Moore WC, Moy J, Naureckas E, Olin JT, Peters SP, Phipatanakul W, Que L, Raissy H, Robison RG, Ross K, Sheehan W, Smith LJ, Solway J, Sorkness CA, Sullivan-Vedder L, Wenzel S, White S, Israel E. Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. N Engl J Med. 2019 09 26; 381(13):1227-1239.
-
Pineda F, Sheth D, Abe H, Medved M, Karczmar GS. Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
-
Leroux F, Bosc D, Beghyn T, Hermant P, Warenghem S, Landry V, Pottiez V, Guillaume V, Charton J, Herledan A, Urata S, Liang W, Sheng L, Tang WJ, Deprez B, Deprez-Poulain R. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur J Med Chem. 2019 Oct 01; 179:557-566.
-
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
-
Anitescu M. The patient with substance use disorder. Curr Opin Anaesthesiol. 2019 Jun; 32(3):427-437.
-
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
-
Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203.
-
Grant JE, Redden SA, Chamberlain SR. Milk Thistle Treatment for Children and Adults with Trichotillomania: A Double-Blind, Placebo-Controlled, Crossover Negative Study. J Clin Psychopharmacol. 2019 Mar/Apr; 39(2):129-134.
-
Al-Khersan H, Hariprasad SM, Salehi-Had H. Dexamethasone and Anti-VEGF Combination Therapy for the Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2019 01 01; 50(1):4-7.
-
Hantel A, Larson RA. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|